SCHEMBL1661561

SCHEMBL1661561

CCn1nc(-c2cccc(C#N)c2)cc1Oc1ccc(C(F)(F)F)cc1

nearest known ligand 0.40

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PTGDR2 Q9Y5Y4 1/20 0.40
MAT2A P31153 1/20 0.40
TRPA1 O75762 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.38
CTSS P25774 3/20 0.38
CTSK P43235 2/20 0.38
KIF11 P52732 1/20 0.37
ALPL P05186 1/20 0.37
ALPI P09923 1/20 0.37
MET P08581 1/20 0.37
S1PR1 P21453 1/20 0.36
KDM4E B2RXH2 1/20 0.36
LMNA P02545 1/20 0.36
SCN9A Q15858 2/20 0.36
GRIN1 Q05586 1/20 0.36
GRIN2B Q13224 1/20 0.36
PTPN5 P54829 1/20 0.36
CNR2 P34972 1/20 0.36
GRM2 Q14416 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1660602 0.88 GABRG2 (0.42) CTSSCTSKMETSCN9A
SCHEMBL1658717 0.87 KIF11 (0.36) CTSSCTSKKIF11KDM4ELMNA
SCHEMBL1658584 0.84 CTSS (0.38) CTSSCTSKMETKDM4ELMNA
SCHEMBL1660633 0.84 SLC6A4 (0.40) TRPA1LMNASCN9A
SCHEMBL1660606 0.83 MET (0.39) CTSSCTSKMETGRM2
SCHEMBL1659866 0.83 GPR55 (0.39) CTSSCTSKKDM4ESCN9A
SCHEMBL1659865 0.82 CYP1A2 (0.38) CTSSCTSKMET
SCHEMBL1659949 0.82 SCN9A (0.42) PTGDR2MAT2ATRPA1L3MBTL1KIF11
SCHEMBL14718487 0.80 PTGDR2 (0.39) PTGDR2MAT2ATRPA1L3MBTL1CTSS
SCHEMBL6902269 0.79 P2RY14 (0.33) SCN9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8871796-B2 Diaryl ether derivatives as notch sparing gamma secretase inhibitors MERCK SHARP & DOHME CORP. (US) 2014-10-28 US disclosed
US-8871796-B2 Diaryl ether derivatives as notch sparing gamma secretase inhibitors MERCK SHARP & DOHME CORP. (US) 2014-10-28 US disclosed
US-20130053386-A1 DIARYL ETHER DERIVATIVES AS NOTCH SPARING GAMMA SECRETASE INHIBITORS MERCK SHARP & DOHME LLC 2013-02-28 US disclosed
US-20130053386-A1 DIARYL ETHER DERIVATIVES AS NOTCH SPARING GAMMA SECRETASE INHIBITORS MERCK SHARP & DOHME LLC 2013-02-28 US disclosed
EP-2488031-A1 DIARYL ETHER DERIVATIVES AS NOTCH SPARING GAMMA SECRETASE INHIBITORS Merck Sharp & Dohme Corp. (US) 2012-08-22 EP disclosed
WO-2011046774-A1 DIARYL ETHER DERIVATIVES AS NOTCH SPARING GAMMA SECRETASE INHIBITORS MERCK SHARP & DOHME CORP. (US) 2011-04-21 WO disclosed
WO-2011046774-A1 DIARYL ETHER DERIVATIVES AS NOTCH SPARING GAMMA SECRETASE INHIBITORS MERCK SHARP & DOHME CORP. (US) 2011-04-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130053386-A1 DIARYL ETHER DERIVATIVES AS NOTCH SPARING GAMMA SECRETASE INHIBITORS BACE1, BACE2, GSAP PTGDR2 1751/4885MAT2A 2125/4885TRPA1 2928/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.